Athira Pharma (NASDAQ:ATHA) CEO Mark James Litton Sells 2,586 Shares

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 2,586 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $6.88, for a total value of $17,791.68. Following the completion of the sale, the chief executive officer owned 40,828 shares in the company, valued at approximately $280,896.64. The trade was a 5.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Athira Pharma Trading Down 5.5%

Shares of ATHA opened at $6.58 on Tuesday. The firm has a market capitalization of $25.93 million, a P/E ratio of -0.68 and a beta of 2.79. Athira Pharma, Inc. has a 12-month low of $2.20 and a 12-month high of $8.36. The firm has a fifty day moving average price of $5.03 and a 200-day moving average price of $4.27.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($0.17) by ($1.51). Analysts predict that Athira Pharma, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ATHA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a report on Wednesday, October 8th. Mizuho set a $4.00 target price on Athira Pharma in a report on Friday, September 19th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Athira Pharma has a consensus rating of “Sell” and an average target price of $4.00.

Hedge Funds Weigh In On Athira Pharma

A hedge fund recently bought a new stake in Athira Pharma stock. Focus Partners Wealth bought a new position in shares of Athira Pharma, Inc. (NASDAQ:ATHA) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,415 shares of the company’s stock, valued at approximately $35,000. Focus Partners Wealth owned 0.21% of Athira Pharma as of its most recent SEC filing. 57.12% of the stock is owned by institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.